RuiPai Medical Completes Nearly RMB 100 Million Series A Funding to Strengthen R&D and Product Pipeline

On December 21, Guangzhou Ruipai Medical Devices Co., Ltd. (hereinafter referred to as “REDPINE”), a manufacturer of single-use endoscopes, announced the completion of its Series A financing round, raising nearly RMB 100 million. The round was led by SDAO Capital, with existing shareholder Oriza Holdings participating in the follow-on investment. The funds raised will be used to further consolidate and expand the product R&D pipeline, accelerate the deployment of automated production lines, and increase brand marketing efforts.

As one of the innovative typical scenarios of natural orifice transluminal endoscopic surgery (NOTES), the use of single-use endoscopes can effectively prevent cross-infection, improve treatment efficiency per unit, significantly reduce medical costs, and alleviate the financial burden on patients.

Since its inception, REDPINE has been committed to providing cost-effective, comprehensive solutions for minimally invasive surgeries, including single-use endoscopes. Although REDPINE was established in 2015, its team began strategizing in the field of single-use endoscopy as early as 2010.

It is understood that REDPINE boasts an international team of expert technicians and has accumulated substantial technical reserves. As a national high-tech enterprise, REDPINE remains committed to independent research and development, ensuring that all its products possess full intellectual property rights and have secured multiple national patents. Currently, REDPINE has developed a diverse portfolio of self-developed products, covering numerous departments including urology, gynecology, otolaryngology, respiratory medicine, and general surgery, with its sales network spanning across China. Furthermore, two of REDPINE’s products already launched in the Chinese market have obtained CE certification, and the company is currently working to establish its sales network in overseas markets.

Notably, in July and August 2020, REDPINE obtained Class III medical device registration certificates for two products: the “Single-Use Electronic Cystoscope” and the “Single-Use Electronic Ureterorenoscope Catheter,” respectively, becoming the manufacturer with the largest number of domestic Class III single-use endoscope product registration certificates. Among these, REDPINE’s independently developed “Single-Use Electronic Cystoscope” is highly competitive on a global scale.

Disposable Electronic Cystoscope

Since its establishment, REDPINE has successively built thousands of square meters of ISO Class 100,000 cleanroom facilities, an ISO Class 10,000 physicochemical laboratory, as well as systematic laboratories and workshops including active device production workshops and R&D centers. Upholding high-standard international concepts, REDPINE’s GMP-compliant production workshops, which meet the requirements for the manufacturing of Class II/III medical devices, have passed acceptance inspection. This enables large-scale production, generating hundreds of millions of yuan in additional output value.

 Disposable Electronic Ureteropyeloscope Endoscopic Catheter

Mr. Yi Feng, founder of REDPINE, stated, “REDPINE will continue to deepen product innovation, focus on the minimally invasive field with a primary emphasis on single-use endoscopes, expand its product portfolio, scale up mass production capabilities, control costs, and accelerate the iteration of product technologies. REDPINE aims not only to become the most valuable manufacturer of single-use endoscopes but also to deliver social benefits by achieving full-department coverage of single-use electronic endoscopes, ensuring ‘one scope per patient’ to address cross-infection risks associated with endoscopic examination and treatment, thereby allowing medical technology to truly benefit patients.”

Ms. Lin Rui, Partner at F-Prime Capital, stated, “Medical devices have always been one of the core pillars of F-Prime Capital’s investment ecosystem. Through in-depth research, we believe that single-use endoscopes will drive significant transformation in endoscopic diagnosis and treatment, and even the broader field of minimally invasive surgery, by addressing clinical pain points and expanding accessibility, thereby benefiting more patients. REDPINE is a leading enterprise in China’s single-use endoscopy sector. Its founding team boasts extensive industry experience, exceptional execution capabilities, and profound technological expertise. We look forward to supporting REDPINE as it continues to raise the bar and lead the single-use endoscopy industry to new heights.”

Mr. Zhao Qun, Partner at Oriza Holdings, stated: “Oriza Holdings has participated in three consecutive rounds of investment in REDPINE. Throughout the company’s development, we have observed the founder’s deep expertise and accumulated experience in the endoscopy field. The team demonstrates strong cohesion, high execution capability, extensive industry experience, and outstanding commercialization abilities. It holds significant advantages in product portfolio strategy and process development for disposable endoscopes. We are highly optimistic about the company’s independent R&D capabilities, product line expansion, and the substantial commercial potential of its disposable endoscope product line in the future.”

Founded in 2015, REDPINE is a global provider specializing in comprehensive solutions for minimally invasive surgeries using single-use endoscopes. Its product development portfolio covers urology, gynecology, otolaryngology, pulmonology, and general surgery. As an emerging force in the field of single-use endoscopes, REDPINE is the first company in China to obtain a Class III registration certificate for a single-use electronic cystoscope, and it currently holds the largest number of Class III registration certificates in the single-use endoscope sector.

Fidelity International is a global private investment firm backed by Fidelity. Leveraging its unique capital structure, Fidelity International can flexibly deploy capital to support innovative companies in disrupting or leading their markets, helping entrepreneurs realize their ambitions. Currently, together with affiliated funds under Fidelity, it ranks among the top ten venture capital firms globally. Our global ecosystem continues to provide portfolio companies with substantial talent pools and deep local expertise to support their business growth.

STO has over 20 years of venture capital experience in China, having invested in more than 100 companies in the healthcare and technological innovation sectors. Over the past decade, we have invested nearly $6.5 billion in startups worldwide.

Oriza Holdings, a member enterprise of Suzhou Oriza Holdings Co., Ltd., is a market-oriented, specialized early-stage equity investment platform. It focuses on investment opportunities in startups and growth-stage enterprises within the Healthcare and TMT sectors. The firm manages ten funds with a total scale of approximately RMB 3.5 billion, comprising both VC funds and angel funds targeted at specific regions.

Oriza Holdings maintains an investment style focused on early-stage ventures, with a preference for technology-driven companies and a strong commitment to its promises, earning it a solid reputation among early-stage tech startups. To date, it has invested in and managed over 180 high-quality enterprises, including Ascentage Pharma, CStone Pharmaceuticals, JW Therapeutics, Beiren Robotics, TZTEK, Cambricon, Biocytogen, BeiGene, Singlera Genomics, Zhizhu Technology, CloudWalk Technology, and Mushroom IoT.